irinotecan has been researched along with raltegravir potassium in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheong, PF; Fan, L; Goh, BC; Hee, KH; Lee, LS; Lee, SC; Sapari, NS; Seng, KY; Soh, TI; Soo, R; Soong, R; Wang, LZ; Wong, A; Yong, WP | 1 |
1 trial(s) available for irinotecan and raltegravir potassium
| Article | Year |
|---|---|
Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Phenotype; Raltegravir Potassium | 2016 |